CMS says most Medicare GLP-1 Bridge prior authorizations clear in under 12 hours

Federal health officials say most prior authorization requests for the Medicare GLP-1 Bridge are decided in less than 12 hours, and they confirmed that a denial under the program does not carry a formal appeals process ^[1].

The Bridge is a short-term demonstration run by the Centers for Medicare & Medicaid Services that gives eligible Medicare Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026, through December 31, 2027 ^[2]. CMS has set a 72-hour standard: prescribers and patients are to be notified of a prior authorization decision within 72 hours of submission ^[2]. Officials told AARP that the Bridge has generally beaten that target, with most determinations completed in under 12 hours, and that most requests arrive electronically rather than by fax ^[1].

No formal appeal for a Bridge denial

A CMS official confirmed there is no formal appeals process when the Bridge denies a request ^[1]. A prescriber can correct and resubmit the request with accurate or new information, but beneficiaries have appeal rights only for GLP-1 coverage decisions issued under the Part D benefit, not for Bridge decisions ^[1].

CMS has not reported how many Bridge requests are denied, or how often a corrected resubmission succeeds. Those figures have not been disclosed.

Who qualifies and what is covered

The Bridge covers Foundayo (orforglipron), Wegovy (semaglutide) injection and tablets, and the KwikPen formulation of Zepbound (tirzepatide) when the drugs are prescribed to reduce excess body weight and maintain weight loss, with a $50 copay ^[2]. Only the KwikPen form of Zepbound is included; the single-dose vial and single-dose pen are not, and pen needles are not covered ^[2].

To qualify, a prescriber must attest through a prior authorization request that the patient meets one of several criteria: a BMI of 35 or higher; a BMI of 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure, or chronic kidney disease stage 3a or above; or a BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease ^[2]. Patients must also be 18 or older and use the drug alongside lifestyle changes including structured nutrition and physical activity ^[2].

People with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic MASH get GLP-1 coverage through their Part D plan and are not eligible for the Bridge, even if they meet its clinical criteria ^[2].

Approvals are valid through December 31, 2027, and refills do not need a new prior authorization unless a patient switches from one covered GLP-1 drug to another ^[2]. Humana, which administers the Limited Income Newly Eligible Transition program, serves as the Bridge's central processor for prior authorization, claims, and payment to pharmacies ^[2].

Why it matters for patients

A Bridge denial works differently from a standard insurance denial. Because the program operates outside the Part D benefit's coverage and payment flow, the usual Part D appeal rights do not apply to a Bridge decision ^[1][2]. The practical path after a denial runs through the prescriber, who can correct the paperwork or add new clinical information and submit it again ^[1]. Patients who want a denial reconsidered may need to ask their prescriber what was missing or what has changed.

Timing also works differently. With most decisions reported inside 12 hours ^[1] against a formal 72-hour standard ^[2], a resubmission does not necessarily mean a long wait, although CMS has not published average turnaround times for resubmitted requests.

One eligibility limit is spelled out in CMS guidance: a patient approved through the Bridge who later fills a GLP-1 prescription through their Part D plan becomes ineligible for the Bridge, and a refill attempt will be rejected at the pharmacy for that reason ^[2].

What happens next

The Bridge is scheduled to run through December 31, 2027, and prior authorization approvals are valid through that date ^[2]. CMS has not said whether it will add a formal appeals pathway for Bridge denials; that has not been disclosed.